source
- CellCentric secures $220 million Series D to advance oral multiple myeloma drug inobrodibCellCentric, a biotech focused on multiple myeloma, announced a $220 million Series D financing led by Venrock. The capital will fund ongoing Phase 2 trials and a planned Phase 3 study of its oral…
- Sanofi requests removal of teplizumab from FDA fast-track voucher program after director disputeSanofi has formally asked the Food and Drug Administration to withdraw its type 1 diabetes therapy, teplizumab, from the new speedy review voucher program overseen by Commissioner Marty Makary. Th…